(Q35118834)

English

Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011) (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

phase I clinical trial

0 references

John R. Mascola

10

object named as

John R Mascola

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

11

object named as

Gary J Nabel

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Barney S. Graham

12

object named as

Barney S Graham

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Julie Ledgerwood

2

object named as

Julie E Ledgerwood

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

8

object named as

Mario Roederer

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1

object named as

Mary E Enama

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Ingelise J Gordon

5

object named as

Ingelise J Gordon

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

9

object named as

Richard A Koup

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

LaSonji A. Holman

6

object named as

LaSonji Holman

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

4

object named as

Martha C Nason

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

3

object named as

Laura Novik

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Robert T Bailer

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

VRC 011 Study Team

13

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

0 references

publication date

12 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

e91366

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

copyright license

Creative Commons CC0 License

12 March 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted, dedicated to the public domain by copyright holder

0 references

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Immunization with DNA through the skin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Dendritic cells and the control of immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3951381

9 July 2018

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0091366

21 January 2018

HIV-infected Langerhans cells preferentially transmit virus to proliferating autologous CD4+ memory T cells located within Langerhans cell-T cell clusters

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0091366

21 January 2018

Low Dose Intradermal Versus High Dose Intramuscular Hepatitis B Vaccination in Patients on Chronic Hemodialysis

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0091366

21 January 2018

Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/24621858

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0091366

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

2014PLoSO...991366E

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35118834&oldid=1980729793"